APA (7th ed.) Citation

Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., . . . Govindan, R. (2013). PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer. Journal of clinical oncology, 31(34), 4349-4357. https://doi.org/10.1200/JCO.2012.47.9626

Chicago Style (17th ed.) Citation

Patel, Jyoti D., et al. "PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 31, no. 34 (2013): 4349-4357. https://doi.org/10.1200/JCO.2012.47.9626.

MLA (9th ed.) Citation

Patel, Jyoti D., et al. "PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer." Journal of Clinical Oncology, vol. 31, no. 34, 2013, pp. 4349-4357, https://doi.org/10.1200/JCO.2012.47.9626.